U.S. Supreme Court allows suit over Vioxx risks

The U.S. Supreme Court has ruled unanimously that a shareholder lawsuit can proceed against Merck & Co., maker of the blockbuster drug Vioxx.  At issue in the case is whether Merck provided doctors and patients with enough information about the drug's risks.  Merck shareholders lost a combined $28 billion overnight when problems with Vioxx became inescapable. 

After FDA warnings, Vioxx was pulled from the market because it dangerously increased patients' risks of heart attack, stroke and death.  Merck has since been sued by numerous patients and survivors who have suffered serious medical conditions they believe was caused by Vioxx.  Several insurance companies have also sued Merck for reimbursement of the costs for covering prescriptions of this drug. 

Yaz birth control deaths

Yaz and Yasmin are two of the most popular oral contraceptives on the market. However, tragically, these birth control pills have proven fatal for at least 50 women, according to reports made to the FDA. Yaz and Yasmin present an increased risk of potentially fatal side effects over other birth control pills.

 Causes of Yaz and Yasmin deaths

Numerous life-threatening side effects are associated with the use of Yaz and Yasmin, including:

  • Deep vein thrombosis
  • Heart attack
  • Blood clots
  • Liver damage
  • Pulmonary embolism
  • Stroke

If a woman does not receive adequate and immediate treatment for any of the above conditions, these side-effects can result in death.

Increased risk for Yaz and Yasmin fatal side effects

Yaz and Yasmin are more dangerous for some women than others. Women with the highest risk of developing a fatal Yasmin/Yaz side effect are those who:

  • Are over the age of 35
  • Are obese
  • Excessively consume alcohol or use illicit drugs
  • Have heart disease
  • Are undergoing hormone therapy
  • Smoke
  • Have had a stroke
  • Have high cholesterol
  • Have high blood pressure

Yaz and Yasmin wrongful death lawsuits

If you have lost a loved one or family member due to fatal side effects from Yaz or Yasmin, you should contact a Yaz/Yasmin lawsuit attorney immediately about bringing a wrongful death lawsuit.

A successful Yaz wrongful death lawsuit can result in compensation for funeral and burial expenses, medical expenses and pain and suffering.  

Yaz and arrhythmia

Women who take Yaz or Yasmin should be aware that these birth control pills present an increased risk of arrhythmia, which is an irregular heartbeat.

Under normal circumstances, your heart beats at a rate that is relative to your current level of activity and comfort. An arrhythmia occurs when your heart rate becomes abnormal for some reason.

Arrhythmias can be placed into one of two main categories:

Tachycardia: Tachycardia occurs when the heart is beating too fast, specifically, at a rate of over 100 beats per minute.

Bradycardia: Bradycardia occurs when a person’s heart rate is too slow, specifically, at rate of less than 60 beats per minute for an adult who is awake.

If your heart rate drops below 50 beats per minute, enough blood may not be pumping to your organs. As a result, you can begin to experience serious side effects, including:

  • Dizziness
  • Fatigue
  • Chest pains
  • Fainting
  • Confusion
  • Heart palpitations
  • Weakness
  • Shortness of breath

In the worst cases, complications from arrhythmia can include:

  • Stroke
  • Cardiac arrest
  • Blood clots
  • Death

Sadly, there is no cure for arrhythmia. Instead, patients must undergo long-term treatments and rehabilitation as well as attend regular checkups.

If you believe you have experienced arrhythmia as a result of taking Yasmin or Yaz, you should immediately contact your physician. Additionally, you can also contact the Yaz and Yasmin lawsuit attorneys of Fears | Nachawati for free legal advice.

Women who have been injured, including by arrhythmias, as a result of taking Yaz or Yasmin birth control may be able to bring a lawsuit against the maker of these drugs.

Number of Yaz and Yasmin lawsuits filed against Bayer now exceeds one thousand

The number of lawsuits filed over the birth control pills Yaz and Yasmin is now at nearly 1,100. This is according to an annual report released by Bayer, the manufacturer of Yasmin and Yaz.

Experts are predicting that the number will continue to rise as thousands of women in both Canada and the United States are considering bringing lawsuits after suffering injuries from taking Yasmin and Yaz.

According to Bayer’s 2009 annual report, which was released last month, among the lawsuits filed have been five Yaz and Yasmin class action lawsuits – three in the United States and two in Canada.

The lawsuits all involve similar issues, which are claims that Yaz, Yasmin and the generic version Ocella increase a woman’s risk of suffering a heart attack, stroke, deep vein thrombosis, pulmonary embolism or gallbladder disease, among other injuries. At least 50 deaths in the United States alone have been linked to the use of Yaz or Yasmin.

In their Yasmin and Yaz lawsuits, the plaintiffs are arguing that Bayer failed to perform adequate research on the safety of the birth control pills and failed to warn users of the increased health risks associated with Yaz and Yasmin.  

Additionally, many of the Yaz and Yasmin lawsuits allege that Bayer was deceptive in its advertising of the birth control pills, over-emphasizing certain supposed benefits of the drugs without also fully disclosing the  potential increased risks of serious side effects posed by Yaz and Yasmin.

In fact, Bayer was formally warned about the deceptive advertising by the FDA and subsequently forced to run a series of ads correcting the misleading claims made in previous commercials.

If you or someone you love has been injured as a result of taking Yaz, Yasmin or Ocella, contact a Yaz/Yasmin lawsuit attorney today for legal advice.

Yaz and Yasmin lawsuits given mass tort designation in New Jersey

All Yasmin, Yaz and Ocella lawsuits filed in New Jersey state courts have been consolidated as a mass tort. These Yaz and Yasmin lawsuits will now be centralized under one judge for coordinated handling of the cases.

On February 18th, New Jersey’s Administrative Office of the Courts ordered that all Yaz, Yasmin and Ocella litigation in the state be assigned to Judge Brian R. Martinotti. Judge Martinotti presides over Bergen County Superior Court. All case management and trial issues in pending and future Yaz, Yasmin and Ocella lawsuits will now be overseen by Judge Martinotti.

The consolidation was requested by Judge Donald Volkert jr., who sits in Passaic County where more than a dozen Yasmin and Yaz lawsuits are pending.

The purpose of consolidating the Yaz lawsuits and Yasmin lawsuits as a mass tort is to avoid duplication and prevent conflicting rulings that may arise if the numerous cases are tried throughout the state.

Note, however, that the cases will remain individual actions and have not been consolidated. Moreover, Judge Martinotti has the discretion to send the cases back to the original county where they were filed for either resolution or trial.

This latest mass tort designation is not the first time that Yaz and Yasmin lawsuits have been consolidated. In October of 2009, all currently pending Yasmin and Yaz lawsuits in federal courts were consolidated for coordinated and centralized pre-trial proceedings. Those proceedings will be overseen by Judge David R. Herndon of the District Court for the Southern District of Illinois.

Also, all pending Yasmin and Yaz lawsuits in Pennsylvania state courts were consolidated last September.

In general, the Yaz, Yasmin and Ocella lawsuits center on the increased risk of heart attack, heart arrhythmias, blood clots, stroke, embolisms and gall bladder disease presented by the birth control pills.

Additionally, these birth control pills may cause a dangerous increase in a woman’s level of potassium, leading to a condition called hyperkalemia. Hyperkalemia can result in serious health problems.

For more on the recent New Jersey mass tort designation of Yasmin, Yaz and Ocella lawsuits, click here for the complete article.

Yaz birth control and increased potassium levels

Potassium is an essential nutrient, necessary for normal cell functioning. However, an abnormal increase in the body’s level of potassium can lead to serious and life-threatening conditions, such as cardiac arrest and arrhythmia.

The birth control pills Yaz, Yasmin and Ocella may have a much greater effect on a woman’s potassium levels than other birth control pills. The reason is that Yaz and Yasmin contain the progestin drospirenone, and drospirenone may significantly increase potassium levels.

Yasmin, Yaz and Ocella all contain 3 mg of drospirenone. The condition of elevated potassium levels associated with drospirenone is known as hyperkalemia.

Symptoms of high levels of potassium in the blood include:

  • Nausea
  • Irregular heartbeat
  • Weaknesses
  • Weak, slow or absent pulse
  • Changes in breathing patterns
  • Loss of consciousness

If you or someone you love has suffered an injury because of an increase in potassium levels caused by taking Yaz or Yasmin, contact the Yaz/Yasmin lawyers of Fears | Nachawati today to receive free legal advice.

Pre-trial hearings in close to 25,000 Yaz/Yasmin lawsuits are underway in Illinois

Pre-trial proceedings for nearly 25,000 Yaz and Yasmin lawsuits are underway in a federal courthouse in East St. Louis, Illinois.

Yaz and Yasmin lawsuits have been filed by women all over the United States, but all the cases will be handled by U.S. District Chief Judge David Herndon as a multidistrict litigation assignment.

Herndon will be presiding over the pretrial discovery. He may then hold “bellwether trials” that will serve as examples for courts in other districts around the country, says Herndon.

In multidistrict litigation (MDL), civil lawsuits making similar legal claims filed against a common defendant in different federal districts are moved to a single district for pre-trial matters, such as discovery and evidentiary rulings, in an effort to avoid duplicate fact-finding and inconsistent pretrial rulings.

The decision to hand the cases to Herndon was made by the Judicial Panel on Multidistrict Litigation in Washington D.C. The panel is made up of seven federal judges who are appointed by U.S. Supreme Court Chief Justice John Roberts.

The defendant in these lawsuits is Bayer Corp., the maker of the birth control pills Yaz and Yasmin. In the Yaz/Yasmin lawsuits, the plaintiffs are alleging that the drugs cause heart attacks, strokes, pulmonary embolism, gallbladder disease, cardiac arrhythmia, kidney failure and even sudden death.

Health risks associated with Yaz and Yasmin have been linked to the drugs’ use of a new type of progestin called drospirenone. This hormone, which is not used in other birth control pills, may increase potassium levels in the blood, leading to a condition known as hyperkalemia.

If you or someone you love has been injured by taking Yaz or Yasmin, contact Fears | Nachawati today to receive free legal advice.

For more on the Yaz/Yasmin pre-trial proceedings, click here for the article from the Belleville News-Democrat.

Yaz and gallbladder disease

Gallbladder disease is a potential – and serious – side effect of Yaz and Yasmin birth control. Gallbladder disease includes infection, stones, inflammation or obstruction of the gallbladder. Women from all over the United States are seeking the counsel of Yaz and Yasmin lawyers after developing gallbladder disease as a result of taking these birth control pills.

The function of the gallbladder, which is located under the liver, is to store and concentrate the bile produced by the liver. This bile helps your body digest fats and is released from the gallbladder into the upper small intestine. Gallbladder disease is a result of a condition that slows or obstructs the flow of bile out of the gallbladder.

Symptoms of gallbladder disease include:

  • Fever
  • Heartburn
  • Nausea
  • Vomiting
  • Chest pain
  • Chills
  • Shaking
  • Abdominal pain

If you have developed gallbladder disease as a result of taking Yaz, Yasmin or Ocella, you should seek the immediate advice of a Yaz/Yasmin lawyer. A Yaz lawyer can advise you on your legal rights and help you understand your options, including bringing a Yaz or Yasmin lawsuit.

Yaz/Yasmin pulmonary embolism

The birth control pills Yaz and Yasmin have been found to increase the risk of pulmonary embolism. Pulmonary embolism is a medical condition that occurs when an artery in the lung is blocked, preventing blood from getting to the lungs.

Yasmin and Yaz increase the risk of blood clots, which are the most common cause of pulmonary embolisms. A pulmonary embolism can occur when a blood clot breaks free from where it formed and travels through the blood stream to the lungs.

Symptoms of a pulmonary embolism include:

  • Rapid heart beat
  • Sudden shortness of breath
  • Excessive sweating
  • Chest pain
  • Fever
  • Leg swelling
  • Fainting or lightheadedness
  • Wheezing
  • Weak pulse
  • Anxiety

Pulmonary embolisms can be highly fatal. About one third of people with an undiagnosed and untreated pulmonary embolism will die. Those who do survive may suffer from heart damage or pulmonary hypertension.

If you or someone you loved has suffered a pulmonary embolism or other injury as a result of taking Yaz or Yasmin, contact the Yaz lawyers of Fears | Nachawati today for free legal advice. To speak with a Yasmin lawyer, simply email us or phone us toll free at 1.866.705.7584.

Yaz side effects

Yaz and Yasmin have recently been the subject of numerous lawsuits across the country as women taking these fourth generation birth control pills have experienced serious and sometimes deadly side effects.

Yasmin and Yaz contain a progestin called “drospirenone,” which poses increased health risks over birth controls containing other types of progestin. Drospirenone is unique to Yaz and Yasmin, making these birth control pills, and their generic counterpart Ocella, more dangerous than other pills.

While drospirenone dramatically increases the health risks associated with using birth control, there is no evidence that it makes Yaz or Yasmin more effective at preventing pregnancy than older generation birth control pills.

Yaz/Yasmin side effects may increase the risk of:

  • Heart attack
  • Stroke
  • Kidney stones
  • Gallbladder disease
  • Deep vein thrombosis
  • Pulmonary embolism
  • Cardiac arrhythmia
  • Pancreatitis
  • Death

If you or a loved one has been injured as the result of taking Yaz or Yasmin, contact Fears | Nachawati today for free legal advice. To speak with one of our Yaz/Yasmin lawyers at no charge, email us or phone us toll free at 1.866.705.7584.

What damages can I recover in my Yasmin/Yaz lawsuit?

Women across the United States are bringing Yaz and Yasmin lawsuits because they have suffered serious, adverse side-effects after taking these birth control pills.

If you have been injured by taking Yaz or Yasmin, you may be entitled to financial compensation for your injuries and related expenses.

“Damages” is the legal term for the financial compensation awarded to a plaintiff in a successful lawsuit. A woman who successfully brings a Yasmin or Yaz lawsuit will be awarded damages that represent compensation for her physical injuries, emotional suffering and financial losses.

The damages you could potentially recover if you win your Yaz/Yasmin lawsuit include:

  • Medical expenses, both past and future
  • Long-term care
  • Out-of-pocket expenses
  • Lost wages
  • Loss of future earnings
  • Pain and suffering
  • Emotional trauma

For free legal advice about Yaz and Yasmin lawsuits, contact Fears | Nachawati today. To receive your no charge consultation with one of our Yaz/Yasmin lawsuit attorneys, simply email us or phone us toll free at 1.866.705.7584.

Yaz and abnormal blood clots

Yaz and Yasmin are known to pose grave health risks to the women who take them. These risks include abnormal blood clotting and, as a result, strokes and heart attacks. In fact, the birth control pills Yaz and Yasmin have been reported to increase the risk of blood clots by more than 600%.

This increased risk of blood clots comes from the key ingredient in Yaz and Yasmin: Drospirenone. Yaz, Yasmin and Ocella are the only birth control pills that use drospirenone.

Blood clotting is a normal and necessary function of the body. However, Yasmin and Yaz can cause your blood to clot when it is unnecessary and can cause clots to form in your blood vessels, veins and arteries.

The danger arises when one of these abnormal blood clots breaks away from the vessel, vein or artery on which it formed and enters the blood stream. The clot can potentially cause a blockage near the heart, preventing blood from reaching the heart and resulting in a heart attack.

Another danger is that of the abnormal blood clot traveling through the blood stream to the brain. Again, a blockage can be created, preventing blood from flowing to the brain and resulting in a stroke.

If you have been injured by taking Yaz, Yasmin or Ocella, contact Fears | Nachawati today for free legal assistance. To speak with a Yaz lawsuit attorney today, simply email us or phone us toll free at 1.866.705.7584.

Has Yaz or Yasmin been recalled?

No, neither Yaz nor Yasmin have been recalled. However, the drugs have both been the subject of numerous personal injury lawsuits around the nation. The maker of Yaz and Yasmin, Bayer HealthCare Pharmaceuticals, also received a warning letter from the FDA over misleading advertising.

Even though neither type of birth control has been recalled, the fact remains that both drugs pose the serious risk of grave, even deadly, side effects. Yasmin and Yaz have been linked to heart attacks, strokes, gallstones, deep vein thrombosis and pulmonary embolisms.

If you have been injured by taking Yaz or Yasmin, contact Fears | Nachawati today for free legal advice. To speak directly with a Yaz and Yasmin lawsuit attorney, simply email us or phone us on our toll free number at1.866.705.7584.

What should I do if I have been harmed by taking Yaz or Yasmin?

If you believe you have been harmed or injured by taking the birth control pills Yaz or Yasmin, seek immediate medial attention. Make an appointment with your physician as soon as possible. If your side effects are diagnosed and treated early, you may be able to avoid serious medical complications.

After you have sought medical attention, contact the Yaz and Yasmin lawsuit lawyers of Fears | Nachawati to learn about your legal rights and options. Women all over the country have filed lawsuits against the makers of Yasmin and Yaz because they have suffered severe side effects as a result of taking these birth control pills.

To find out if you are eligible to bring a Yaz or Yasmin lawsuit, contact us today by email or by phoning us toll free at 1.866.705.7584.

New Jersey judge seeks mass tort status for Yaz and Yasmin lawsuits

A Passaic County, New Jersey, judge has requested mass tort status for all of the state’s Yasmin, Yaz and Ocella lawsuits.

Requesting the consolidation is Judge Donald Volkert jr. Already in Passaic County, where Volkert sits, there are more than a dozen Yaz andYasmin lawsuits pending.

There are 26 additional Yaz and Yasmin mean lawsuits pending in other New Jersey counties. According to Volkert, Yasmin and Yaz plaintiffs lawyers in the state have told him the number could reach 1000. If assigned mass tort status, all the Yaz and Yasmin lawsuits would be assigned to one judge.

Typically mass tort status requests are made by plaintiffs’ lawyers, but the courts do allow judges to make these applications as well. Volkert acted out of concern for strain on the judiciary’s resources.

Volkert’s proposal is being considered by New Jersey’s Administrative Office of the Courts, and a ruling is expected sometime in early 2010.

Click here for more on the mass tort status of Yaz and Yasmin lawsuits in New Jersey.

If you or someone you love has been injured as a result of using Yaz or Yasmin birth-control pills, contact Fears | Nachawati today for free legal advice. You can email us at info@fnlawfirm.com or call our toll-free number at 1.866.705.7584.

Yaz Lawyers - What will legal help cost me?

Yaz and Yasmin lawyers work on a contingency basis which means there are no upfront legal fees for the client.  Any and all payment to the Yaz lawyer will be paid out of any settlement or verdict if the case is tried.  Yaz legal help is widely available, but victims of Yaz should look for Top Yaz Lawyers who have experience battling the big pharmaceutical companies. Deep Vein Thrombosis, Stroke, Embolisms, Death, Clots and Gall bladder complications remain the major events experienced by women across the nation.  Our Yaz lawyers at Fears | Nachawati Law Firm have the experience necessary to represent women hurt by the dangerous drug yaz.  If you are looking for the top and best Yaz lawyers, contact Fears | Nachawati Law Firm by email - mn@fnlawfirm.com or toll free at 1.866.705.7584.

Yaz Lawyers - What will legal help cost me?

Yaz and Yasmin lawyers work on a contingency basis which means there are no upfront legal fees for the client.  Any and all payment to the Yaz lawyer will be paid out of any settlement or verdict if the case is tried.  Yaz legal help is widely available, but victims of Yaz should look for Top Yaz Lawyers who have experience battling the big pharmaceutical companies. Deep Vein Thrombosis, Stroke, Embolisms, Death, Clots and Gall bladder complications remain the major events experienced by women across the nation.  Our Yaz lawyers at Fears | Nachawati Law Firm have the experience necessary to represent women hurt by the dangerous drug yaz.  If you are looking for the top and best Yaz lawyers, contact Fears | Nachawati Law Firm by email - mn@fnlawfirm.com or toll free at 1.866.705.7584.

Texas woman brings Yaz lawsuit, claims birth control pill killed unborn child

A Texas woman has brought a lawsuit against the makers of the Yaz and Yasmin birth control pills. In her Yaz lawsuit, the plaintiff claims that the birth control pills caused a blood clot resulting in the death of her unborn child.

The plaintiff is Candice Richardson. Richardson’s suit names Bayer Healthcare LLC and Bayer Healthcare Pharmaceuticals, Inc. as defendants. Her lawsuit alleges that the companies misrepresented the benefits of Yaz and Yasmin while also hiding the risk of serious side effects.

According to Richardson’s lawsuit, Yasmin and/or Yaz caused her to suffer “blood clotting and related injuries,” which resulted in hospitalization and, ultimately, the “stillbirth of her daughter at 27 weeks of pregnancy.”

The lawsuit does not specify whether Richardson was taking Yasmin or Yaz at the time she developed the blood clot.

In the lawsuit, Richardson alleges that Bayer produced a defective product that resulted in both injuries to herself and the wrongful death of her unborn baby. Causes of action listed in the lawsuit include:

  • Negligence
  • Negligent misrepresentation
  • Manufacturing and design defect
  • Defect caused by inadequate warnings
  • Breach of warranty
  • Violations of the Deceptive Trade Practices Act

Richardson is seeking damages for pain and suffering and medical expenses as well as punitive damages.

Click here to read more about Richardson’s Yaz/Yasmin lawsuit.

Fears | Nachawati represents individuals injured by Yaz or Yasmin birth control pills in bringing lawsuits against the manufacturers. Contact us today for free legal advice about your potential Yasmin or Yaz lawsuit by emailing us atinfo@fnlawfirm.com or calling our toll-free number at 1.866.705.7584.

Yaz Birth Control and Yaz Legal Help

Yaz Birth Control has created the need for legal help and left many women with questions concerning the safety of Yaz or Yasmin.  Yaz side effects can include: Heart Attack, Stroke, Deep Vein Thrombosis, Embolisms, Death and Gall Bladder complications. Our Yaz lawyers have significant experience battling big pharmaceutical companies.  We anticipate the Yaz manufacturer, Bayer, to vigorously defend itself against the cases that are expected to be filed across the nation. Approximately 132 cases have been filed as of October 2009. The number of death and serious injuries allegedly caused by Yaz continue to mount. For Yaz legal help or free information about the Yaz lawsuit, contact our law firm - mn@fnlawfirm.com or toll free at 1.866.705.7584.

Yaz Lawyers - The Importance of Hiring a Yaz Lawyer, Attorney or Law Firm Early On

Yaz claims and Yasmin lawsuits continue to rise as our Yaz lawyers and a handful of other firms continue to build cases against Bayer in connection with its marketing of Yaz for uses that the FDA did not approve. Most Yaz clients our firm represent have suffered a stroke, heart attack, or deep vein thrombosis. Some clients have also suffered from gall bladder disease.  Most of the suits that have been filed so far are being removed from state court and transferred to Illinois' Southern District Court, where The Honorable Judge Herndon presides over the Yaz cases. It is important for women who have suffered Yaz injuries to come forward early on and hire a Yaz lawyer or Yasmin law firm to ensure that the evidence continues to rise against Bayer and its subsidiaries through additional testimony concerning injuries. Anyone who has suffered from an injury because of Yaz usage anywhere in the nation is encouraged to contact our Yaz lawyers directly by email - mn@fnlawfirm.com - or by toll free telephone for a free consultation. 1.866.705.7584.

Yaz Lawsuits consolidated and assigned to Judge Herndon

Yaz lawyers who previously filed lawsuits against Bayer for injuries have learned that their cases have been consolidated and transferred to Judge Herndon, a U.S. District Judge for the Southern District of Illinois. Our law firm has been actively involved in reviewing and accepting Yaz cases on a nationwide basis. Many affected by Yaz need legal help or have questions, but do not know which lawyers handle these cases.  These individuals should contact our firm, Fears | Nachawati, to discuss their potential case and get answers and legal help to questions concerning Yaz side effects. Free consultations are being offered to individuals who have suffered Yaz injuries, including death, heart attack, stroke, deep vein thrombosis (dvt), or pulmonary embolisms. Contact our firm today to find out your legal rights - 1.866.705.7584 or by email at mn@fnlawfirm.com.
 

Yaz lawsuits: What is Ocella?

Ocella is the generic version of Yasmin. Just like Yasmin, it is a prescription birth control pill…and just like Yasmin, it has proven to be very dangerous.

Ocella, along with Yaz and Yasmin, poses serious risks to the women who take this oral contraceptive. Serious side effects that are associated with Yaz, Yasmin and Ocella include stroke, heart attack and pulmonary embolism. Tragically, these birth control pills have proven fatal in some cases.

Ocella contains the same ingredient that makes Yasmin and Yaz unsafe – drospirenone. It is this ingredient in particular that has been shown to pose grave health risks to users.

If you or a loved one has experienced negative health effects from using Ocella, Yaz or Yasmin, contact Fears | Nachawati today to learn about your legal rights. You will speak with a Yaz lawsuit attorney who can explain your options and answer your questions.To receive your free legal advice, email us at info@fnlawfirm.com or call our toll-free number at 1.866.705.7584.

Hiring the Best Personal Injury Lawyer

People often do not know where to turn when it comes to dealing with a serious personal injury case or finding the best or top injury lawyers.  Here are some factors you should consider when it comes to hiring a personal injury lawyer:

Factors important in hiring the Best Personal Injury Lawyer:

1.  Has the lawyer or law firm your are considering hiring ever tried a lawsuit?  If so, when was their last trial and what was the outcome? 

2.  Has the lawyer you are considering hiring ever been disciplined by the State Bar of Texas? (check www.texasbar.com)

3.  Has the lawyer ever completed a judicial clerkship--a prestiguous honor bestowed on only approximately 2% of lawyers in the nation?

4. Does the lawyer you are considering hiring sound well-informed and knowledgeable regarding personal injury law?

5. Has the lawyer ever settled a case or tried a case and obtained a significant recovery?

6.  Does your lawyer have the necessary resources to prosecute your case?

7.  Can you relate to the lawyer and does your intuition tell you that the lawyer is trustworthy?

8.  Where did the lawyer go to law school, and more importantly, what has the lawyer's practical experience been since law school?  Remember, years of experience does not necessarily mean a more competent lawyer.

This list of factors is non-exclusive.  The author of this article, attorney, Majed Nachawati, is frequently quoted by newspapers, media, and has been recognized as a top lawyer.  Mr. Nachawati is a former judicial law clerk and has settled and tried numerous lawsuits to verdict resulting in large recoveries for his personal injury clients. Questions or comments can be emailed to mn@fnlawfirm.com or by telephone - 1.866.705.7584.

Hiring the Best Personal Injury Lawyer

People often do not know where to turn when it comes to dealing with a serious personal injury case or finding the best or top injury lawyers.  Here are some factors to consider when considering whether hiring a lawyer:

Factors important in hiring the Best Personal Injury Lawyer:

1.  Has the lawyer or law firm your are considering hiring ever tried a lawsuit?  If so, when was their last trial and what was the outcome? 

2.  Has the lawyer you are considering hiring ever been disciplined by the State Bar of Texas? (check www.texasbar.com)

3.  Has the lawyer ever completed a judicial clerkship--a prestiguous honor bestowed on only approximately 2% of lawyers in the nation?

4. Does the lawyer you are considering hiring sound well-informed and knowledgeable regarding personal injury law?

5. Has the lawyer ever settled a case or tried a case and obtained a significant recovery?

6.  Does your lawyer have the necessary resources to prosecute your case?

7.  Can you relate to the lawyer and does your intuition tell you that the lawyer is trustworthy?

8.  Where did the lawyer go to law school, and more importantly, what has the lawyer's practical experience been since law school?  Remember, years of experience does not necessarily mean a more competent lawyer.

This list of factors is non-exclusive.  The author of this article, attorney, Majed Nachawati, is frequently quoted by newspapers, media, and has been recognized as a top lawyer.  Mr. Nachawati is a former judicial law clerk and has settled and tried numerous lawsuits to verdict resulting in large recoveries for his personal injury clients. Questions or comments can be emailed to mn@fnlawfirm.com or by telephone - 1.866.705.7584.

Personal Injury Claims - How long do I have to file suit?

In Texas, the amount of time a person has to file their claim or case with the courts varies according to the type of lawsuit or claim that is filed.  While there are limited exceptions to when limitations expires, a lawsuit or claim should be filed well ahead of the expiration of the applicable limitations statute.  The reasoning for filing well in advance is that many complications could arise in computing the time line, and once the limitations date expires, you generally lose your right to sue forever--something you do not want to happen.  General legal information on some Texas statute of limitations is listed below:

- Personal Injury - 2 years from date of injury

- Injury to Property - 2 years from date of injury

- Product Liability - 2 years

- Wrongful Death - 2 years from date of death

- Minors - does not begin to run until minor reaches age 18

Call the lawyers at Fears | Nachawati Law Firm if you have questions about your potential case and the proper calculation or the statute of limitations. 1.866.705-7584 or info@fnlawfirm.com

 

 

Deadly head-on collision kills father, two children

A father and two of his children were killed in a head-on collision on Highway 71 near Spicewood, Texas. The victims are Russell Rutland and his 4-year-old daughter Maddie and 9-year-old son Hunter.

The accident occurred on Saturday morning, June 6th, when a driver crossed over the double yellow line on Highway 71, heading into oncoming traffic. The vehicle then struck Rutland’s car head on. All three victims died instantly upon impact. Rutland’s two other sons, ages 5 and 9, were also riding in the car and suffered only minor injuries.

The driver responsible for the crash is John Horn, 29. He was arrested on charges of driving without a license and without insurance. Horn has admitted to using meth on Friday night. He tested positive for the drug on the day of his arrest.  Horn will likely be charged with three counts of vehicular homicide.

For more on this story, click here.

If you have been involved in a car accident, you can benefit from the help of a Texas personal injury lawyer. For a free consultation about car accident personal injury claims, contact Fears | Nachawati today. E-mail us at info@fnlawfirm.com or call us on our toll-free number at 1.866.705.7584 for a free consultation.

FDA Recall - Digoxin recalled by Caraco Pharmaceutical Laboratories

Another Digoxin recall was announced by the Food & Drug Administration (FDA) on March 31, 2009.  The digoxin lawyers at our firm, Fears & Nachawati, continue to investigate and actively pursue claims and cases where consumers have been injured by Digoxin and Digitek. 

The FDA posted information listed below about the recall.

Caraco Pharmaceutical Laboratories, Ltd. (NYSE AMEX: CPD), a generic pharmaceutical company, announced that all tablets of Caraco brand Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011, are being voluntarily recalled to the consumer level. The tablets are being recalled because they may differ in size and therefore could have more or less of the active ingredient, digoxin. The recalled tablets were manufactured by Caraco Pharmaceutical Laboratories, Ltd. This recall is being conducted with the knowledge of the Food and Drug Administration. Digoxin is a drug product used to treat heart failure and abnormal heart rhythms. It has a narrow therapeutic index and the existence of higher than labeled dose may pose a risk of digoxin toxicity in patients with renal failure. Digoxin toxicity can cause nausea, vomiting, dizziness, low blood pressure, cardiac instability, and bradycardia. Death can also result from excessive digoxin intake. A lower than labeled dose may pose a risk of lack of efficacy potentially resulting in cardiac instability. The recalled lots of Digoxin are listed below.

Caraco Digoxin 0.125 mg is a scored round biconvex yellow tablet imprinted with “437”

Caraco Digoxin 0.25 mg is a scored round biconvex white tablet imprinted with “441”

NDC Numbers:

Digoxin Tablets, USP, 0.125 mg
57664-437-88 (100-count)
57664-437-18 (1000-count)

Digoxin Tablets, USP, 0.25 mg
57664-441-88 (100-count)
57664-441-18 (1000-count)

Our firm is actively pursuing digitek and digoxin pharmaceutical companies on a nationwide basis.  If you or a loved one has been harmed by digoxin or digitek, call our firm for legal help or for a free legal consultation about your potential digoxin or digitek claim.  Toll Free 1.866.705-7584 or by email at mn@fnlawfirm.com

 

FDA Recalls Hydroxycut Products - 23 Liver Injuries and One Death

Today, partners at Fears & Nachawati Law Firm learned the FDA has recalled Hydroxycut products, popular dietary supplements used for weight loss.  FDA reports indicate that there has been at least one death and 23 Liver injuries linked to the products.  The Hydroxycut products are commonly used as fat burners or energy boosters.  which are also used as energy enhancers and as fat burners.  The 14 Hydroxycut products are manufactured by Lovate Health Sciences Inc. of Oakville, Ontario, and distributed by Lovate Health Sciences USA Inc. of Blasdell, New York. 

The company is voluntarily recalling the following products: Hydroxycut Regular Rapid Release Caplets, Hydroxycut Caffeine-Free Rapid Release Caplets, Hydroxycut Hardcore Liquid Caplets, Hydroxycut Max Liquid Caplets, Hydroxycut Regular Drink Packets, Hydroxycut Caffeine-Free Drink Packets, Hydroxycut Hardcore Drink Packets (Ignition Stix), Hydroxycut Max Drink Packets, Hydroxycut Liquid Shots, Hydroxycut Hardcore RTDs (Ready-to-Drink), Hydroxycut Max Aqua Shed, Hydroxycut 24, Hydroxycut Carb Control and Hydroxycut Natural.

Last year alone, Lovate sold more than 9 million units of Hydroxycut products, which were distributed widely to grocery stores, health food stores and pharmacies.

Although reports of liver damage is rare, common sypmtoms include brown urine, nausea, vomiting, fatigue, stomach pain, itching and light-colored stools.

The Dietary Supplement Health and Education Act of 1994 required manufacturers to ensure a supplement to be safe before marketing. But manufacturers still don't need to register a product with the FDA or get approval before selling a supplement.

A link to the recall can be read here:  http://www.fda.gov/bbs/topics/NEWS/2009/NEW02006.html.

Additional Hydroxycut or legal information can be directed to our office toll free 1.866.705.7584 or mn@fnlawfirm.com.  The attorneys of Fears & Nachawati look forward to a prompt and thorough investigation in connection with any consumers harmed by these dangerous supplements.

Raptiva recalled by the FDA

 

RAPTIVA RECALLED

April 8th, 2009

Today, Genentech announced that it has suspended sales of the psoriasis drug RAPTIVA in the United States due to its links to brain infections. Raptiva has been associated with an increased risk of progressive multifocal leukoencephalopathy (PML). Fears | Nachawati Law Firm is currently evaluating cases on behalf of all Raptiva patients.

 

Fears | Nachawati Law Firm has helped victims of defective drugs and medications obtain justice and hold pharmaceutical companies that have released problematic drugs onto the market accountable.  As new medications are released, some ultimately prove to present as much danger to those who use them as they do potential cures or solutions.  When this happens, victims need an advocate to turn to in order to help them work towards moving past the situation in such a way as the law deems proper.  The defective drugs lawyers at Fears | Nachawati Law Firm work with these clients to help them achieve this end.

Unfortunately, one of those drugs that’s been recently alleged to present an unreasonable danger to those who have used them is Raptiva, a widely used medication that was formulated to help with the treatment and management of psoriasis.  The U.S. Food and Drug Administration (FDA) has recently gotten involved with this situation, and the steps the agency has taken will be detailed below.  In the meantime, you’ll also find an overview of Raptiva and the issues that surround it.

Raptiva’s History and Intended Use

Raptiva is manufactured by Genentech, Inc. and was originally approved for distribution by the FDA in 2003.  Its intended use was to help those who suffered from psoriasis manage the disease more comfortably.  For a time, Raptiva proved to be successful, but recent reports have shown that several serious and sometimes grave side effects followed its use.

According to the National Psoriasis Foundation, Raptiva works by, “blocking the activation of certain immune cells called T cells, and the migration of those cells into the skin. T cells are a type of white blood cell in the body; in psoriasis, once these T cells are mistakenly activated, they can trigger inflammation and other immune responses and fuel the development of psoriasis lesions.

By blocking T-cell activation and the movement of these cells into the skin, Raptiva interrupts the cycle of psoriasis, leading to improvement in symptoms for many people who take it.”

Raptiva’s Side Effects

After a few years on the market, disturbing reports of side effects believed to have been brought about by Raptiva began to surface.  Each of these problems reported are extremely serious in nature, and each is briefly described below.

Viral Meningitis

Viral meningitis is a serious, but rarely fatal disease that infects the fluid in the spinal cord and the fluid that surrounds the brain.  It can only be diagnosed with a spinal fluid tap, and symptoms include:

  • Fever
  • Headache
  • Stiff neck
  • Fatigue

Bacterial Sepsis

Bacterial sepsis is more of a medical term that describes what happens when bacteria invades a person’s bloodstream and causes serious infections in organs such as the kidneys or lungs.  Sepsis can be treated with medication, but it’s also possible that a patient can die from this condition.

Invasive Fungal Disease

Invasive fungal disease is a condition that could actually occur in several different ways, depending on the bacteria involved and the parts of the body that are harmed.  Some of these bacteria can be treated with medication, but others are extremely difficult to handle.

Brain Infection - Encephalopathy

Encephalopathy means an infection that affects the brain, as stated above.  Unfortunately, there are innumerable symptoms that could present themselves when this condition strikes, as different parts of the brain affected will lead to different reactions by the body.

Lymphoma

Raptiva has also shown a tendency to heighten the risk of contracting cancers such as lymphoma, which is a form of cancer that attacks the lymph nodes.  Warning signs of lymphoma include pain and/or swelling of the neck, unexplained weight loss, fever, night sweats and itchiness in several areas of the body.  While lymphoma can be treated, like any other cancer, it can also be fatal.

PML (Progressive Multifocal Leukoencephalopathy)

Progressive Multifocal Leukoencephalopathy (PML) is a very rare disease that, according to the National Institute of Neurological Disorders and Stroke, “progressive multifocal leukoencephalopathy (PML) is caused by the reactivation of a common virus in the central nervous system of immune-compromised individuals.”

Those who take Raptiva are under this cloud of risk, and symptoms of PML include:

  • Clumsiness
  • Progressive weakness
  • Visual problems
  • Difficulty with speech

Unfortunately, since PML affects the brain, the symptoms can be quite diverse and therefore very difficult to diagnose. 

Death and the FDA’s Involvement

As noted above, many of the side effects allegedly linked to Raptiva can lead to the death of patients.  Specifically, three deaths of Raptiva users are what prompted the FDA to get involved.  All of them suffered from PML.  The FDA required Genentech, Inc. to affix a “Black Box” warning to all labels of the medication that clearly state the dangers associated with Raptiva.

 

Contact the lawyers at Fears | Nachawati for free legal information concerning this recalled drug.  Toll free 1.866.705-7584.

 

Supreme Court rules in favor of State rights

At issue was a lawsuit by Vermont guitarist Ms. Levine, who lost an arm to gangrene after Wyeth's anti-nausea drug Phenergan was inadvertently injected into one of her ateries during a push IV injection. Ms. Levine had gone to a clinic for treatment of a migraine headache.

Ms. Levine argued that Phenergan's labeling, though approved by the Food and Drug Administration, didn't provide proper warnings of the risk of administering the drug through a push IV injection instead of using an IV-drip. A Vermont jury awarded her damages.  The Vermont Supreme Court upheld the award, FDA drug regulations don't prevent a company from being sued under state law over drug labeling.

Wyeth argued that Ms. Levine's lawsuit, which was based on Vermont law, should be preempted by federal drug regulations.  The FDA, Wyeth said, knew of the drug's risks and benefits and instructed the drug maker to use labeling that accommodated both.

Washington--The U.S. Supreme Court, in a major loss for pharmaceutical manufacturers, ruled 6-3 Wednesday that a Vermont woman, Diana Levine, is entitled to a 6.7 million judgement against Wyeth for injuries she suffered after taking one of the drug maker's medicines.

Majed Nachawati of the Law Firm of Fears & Nachawati was quoted as saying " This is a victory for every person injured or family destroyed due to very similar circumstances."  The Law Firm of Fears & Nachawati can be contacted for a free consultation at 214-890-0711 or MN@fnlawfirm.com

Trasylol (aprotinin injection)

Trasylol (aprotinin injection) is used for prophylactic use to reduce blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion. On November 5, 2007 The U.S. Food and Drug Administration announced that Bayer Pharmaceuticals (the makers of Trasylol) agreed to the FDA- requested suspension of Trasylol. Trasylol was recalled because heart bypass, heart valve replacement and other cardiac surgery patients who received Trasylol were more likely to die. The deaths were due to:
• kidney failure
• heart failure
• heart attacks
• and strokes the patients suffered following the surgery.

The attorneys of Fears and Nachawati are helping people in cases of Trasylol lawsuits. If you or someone you know needs assistance and require financial compensation due to Trasylol complications or death contact the lawyers at Fears and Nachawati. Fears and Nachawati are located in Dallas, Fort Worth, Austin, Houston, and San Antonio:


Fears and Nachawati Attorneys & Counselors
4925 Greenville Avenue
Suite 715
Dallas, Texas 75206
Phone: (214) 890.0711
mn@fnlawfirm.com

*Principal Office
*Se Habla Espanol





Deaths from Illegal Version Fentanyl

More than 1,000 people died over two years from an illegal version of the painkiller fentanyl, the government reported Thursday in its first national tally of those deaths.

The Dallas Morning News reported, the spike of overdoses seems to have ended, health officials said, pointing to law enforcement's shutdown of a fentanyl operation in Mexico in 2006.

The wave of fentanyl overdoses first came to light in Chicago in 2005, and by 2006 more clusters were identified in Philadelphia, Detroit and other cities.

Hundreds of deaths from the drug were gradually reported, often episodically in local newspapers. Thursday's report from the Centers for Disease Control and Prevention puts the toll at 1,013 deaths from early April 2005 through late March 2007.

"This was really an epidemic," said Dr. Steven Marcus, the executive director of New Jersey's poison control center and a co-author of the new report.

Some deaths from illegal fentanyl still occur, but the worst of the outbreak seems to have ended after authorities shut down a fentanyl-making operation in Toluca, Mexico, in May 2006, said Dr. T. Stephen Jones, the study's lead author.

"It almost disappeared entirely. The shutting down of the Toluca facility was probably a major factor," said Jones, a consultant retired from the CDC.

The new report is being published this week in a CDC's Morbidity and Mortality Weekly Report.

Fentanyl is a prescription painkiller, often prescribed for cancer patients and administered through a patch. But it also is a powerful, euphoria-inducing narcotic, 30 to 50 times more potent than heroin.

Illegally made versions of the drug are sold as a powder, often mixed with cocaine or heroin, and sometimes used as a heroin replacement. It's possible some heroin addicts are unaware fentanyl is part of their injection, some experts say.

Digitek ( Digoxin )

Digitek (digoxin) is a drug that was intended to assist or help people in stabilizing their heart beat. Digitek has been used to treat conditions such as congestive heart failure and atrial fibrillation/atrial flutter (types of fast heartbeats).

The product is made by Totowa LLC and distributed by Mylan Pharmaceuticals Inc., under a “Bertek” label and by UDL Laboratories, Inc., under a “UDL” label.

On April 28, 2008, the U.S. Food and Drug Administration recalled the drug due to potential safety risks. In some instances, Digitek could contain twice the approved level of active ingredient needed.

Serious side effects are:
• Nausea
• Vomiting
• Dizziness
• Low Blood Pressure
• Cardiac instability
• Slow heart beat
• Death
The Lawyers of Fears and Nachawati are helping individuals with lawsuits against the Digitek manufacturers. If you need help or assistance and require medical treatment or financial compensation due to Digitek toxicity or Digitalis Toxicity, contact the lawyers at Fears and Nachawati. Fears and Nachawati Law Firm have offices in Dallas, Fort Worth, Austin, Houston, and San Antonio.

Fears and Nachawati Attorneys & Counselors
4925 Greenville Avenue suite 715
Dallas, TX 75206
Phone: 1 (866) 705.7584
*Principal Office
Se Habla Espanol

Digitek and Dioxin Lawsuit

The Texas Law Firm of Fears | Nachawati continues its investigation concerning a potential Digitek and Digoxin lawsuit on behalf of people suffering from digitalis toxicity and other side effects including nausea, vomiting, dizziness, low blood pressure, irregular heartbeat, and possible death. The manufacturer and distributor of the defective drug include Actavis Totowa, Mylan Pharmaceuticals, Bertek, and UDL Laboratories. The drug’s primary purpose is to treat conditions such as congestive heart failure and atrial fibrillation. However, a recent nationwide recall has been issued because of the possibility that Digoxin tablets may contain double the appropriate thickness in each tablet. In other words, some Digoxin pills contain two times the FDA approved level of active ingredient. The active ingredient in Digitek can cause digitalis toxicity, especially people suffering from renal failure. A Digitek overdose can also result in death. For legal help or free information or possible representation concerning the Digitek/Digoxin recall, contact the lawyers of Fears | Nachawati Law Firm at 1 (866) 705-7584 or by email at mn@fnlawfirm.com.

Drugmaker Merck Misrepresented Vioxx

From CNBC News, A new report in the Journal of the American Medical Association is highly critical of drugmaker Merck and its handling of the painkiller Vioxx.

The JAMA article says Merck Merck & Co IncMRK
40.34 -0.88 -2.13% NYSE

Quote | Chart | News | Profile
[MRK 40.34 -0.88 (-2.13%) ] misrepresented apparent Vioxx-related deaths in studies to see if the drug worked on Alzheimer's Disease.

A review of the clinical trials, which came to light during the Vioxx litigation, shows a three-fold increase in the risk of death among the patients who got Vioxx, according to the peer-reviewed medical journal.

But in a press release, Merck says that after careful analysis there was no suggestion the deaths were caused by the drug and that the JAMA report's conclusions are "false, misleading, or lack context".

Merck voluntarily pulled Vioxx off the market in 2004 because of an increased heart risk. The company has since settled most of the resulting lawsuits for nearly $5 billion.

One of the two authors of the JAMA article was a paid expert witness for Vioxx plaintiffs.

www.cnbc.com/id/24133815/

FDA Issues Alert on Tussionex, a Long-Acting Prescription Cough Medicine

The U.S. Food and Drug Administration issued an alert today on the safe and correct use of Tussionex Pennkinetic Extended-Release Suspension in response to numerous reports of adverse events--including death--associated with the misuse and inappropriate use of this potent cough medication.

Tussionex is a prescription cough medicine containing hydrocodone, a narcotic ingredient, and the antihistamine chlorpheniramine. The product is approved for use in adults and children over the age of six years old, and should be given no more frequently than every 12 hours (“extended-release”).

“There is a real and serious risk for overdosing if this medication is not used according to the labeling,” said Curtis Rosebraugh, M.D., M.P.H., acting director of the FDA's Office of Drug Evaluation II. “Today’s action is an example of the FDA working with drug manufacturers throughout a product’s lifecycle to keep health care professionals and patients informed of new safety data.”

Adverse event reports associated with Tussionex have included life-threatening side effects and deaths in patients, including children. These reports reveal physicians and other health professionals are sometimes prescribing, and patients are sometimes taking, more than the recommended dose or taking the medication more frequently than every 12 hours. The reports also show that Tussionex is sometimes prescribed or given to children less than 6 years old, for whom this medication is not approved.

Highlights of the FDA’s recommendations to health care professionals include:

Tussionex should not be used (is contraindicated) in patients less than 6 years old. FDA has received reports of death in children less than 6 years of age who have been prescribed Tussionex.


Consult the prescribing information to determine the correct dose and dosing frequency of Tussionex. Tussionex is an extended-release formulation that should not be prescribed at an interval less than 12 hours.


Discuss with the patient the amount of and frequency of Tussionex to be given. Instruct patients not to take, and parents not to administer Tussionex more frequently than every 12 hours.
Highlights of the FDA’s recommendations to patients include:

One of the two ingredients in this long-acting cough product is hydrocodone, a narcotic. Too much hydrocodone can cause life-threatening breathing problems and death. Call your doctor right away if you have taken this medicine and have trouble breathing, slow heartbeat, severe sleepiness or cold, clammy skin.


For Tussionex, use a medicine syringe or other device designed to measure liquid medications. A household teaspoon or tablespoon should not be used because the spoons vary in size and you may receive too much or too little of the medicine. Ask your doctor or pharmacist if you are unsure how to measure the medicine.


If the cough is not controlled despite taking the prescribed dose at the recommended interval, talk to your doctor.
The manufacturer of Tussionex Pennkinetic Extended-Release Suspension (UCB Inc, Smyrna, Ga.) has agreed to update the labeling, including information that Tussionex should not be prescribed to or used in children less than 6 years of age, as well as the need for accurate dosing.

For more information and the full list of the FDA's recommendations, visit http://www.fda.gov/cder/drug/infopage/hydrocodone/default.htm

This alert does not impact short-acting cough products containing hydrocodone that can be given every 4 to 6 hours. However, the FDA is reviewing safety information on these other hydrocodone containing cough products and will provide updates as new information becomes available.

The Effects of Trasylol

The lives of 22,000 patients could have been saved if U.S. regulators had been quicker to remove a Bayer AG drug used to stem bleeding during open heart surgery, according to a medical researcher interviewed by CBS Television's 60 Minutes program.

The drug Trasylol was withdrawn in November at the request of the FDA after an observational study linked the medicine to kidney failure requiring dialysis and increased death of those patients.

It had been given to as many as a third of all heart bypass patients in the United States at the height of its use over a period of many years, according to the report.

Dr. Dennis Mangano, the study's researcher, said during the program that 22,000 lives could have been saved if Trasylol had been taken off the market when he first published his study in January 2006, according to a CBS News report on its Web site ahead of a broadcast slated for next Sunday.

He said in the broadcast that Bayer failed to disclose to the FDA during an FDA advisory panel meeting in September 2006 -- at which Mangano's negative findings were discussed -- that the German drugmaker had conducted its own research which confirmed the same dangers established by his study.

The chairman of the FDA advisory panel, Dr. William Hiatt, told 60 Minutes he would have voted to remove Trasylol from the market had he been informed about Bayer's study, according to the CBS report.

Bayer spokeswoman Meredith Fischer said she could not comment about the broadcast until it is aired, including allegations that the drugmaker had failed to protect patients.

She said Bayer is facing a number of product-liability lawsuits filed by patients who had taken the medicine or their families, but said she not know how many lawsuits were filed.

Provided by Reuters.com

Dangerous Deception..

The New England Journal of Medicine reports about the recent drug Trasylol.

September 30 is becoming a day of infamy for drug safety. On that date in 2004, Merck announced that rofecoxib (Vioxx) doubled the risk of myocardial infarction and stroke, and the company withdrew the drug from the market after 5 years of use in more than 20 million patients. On September 30, 2006, a front-page article in the New York Times reported that the Food and Drug Administration (FDA) had issued a warning that the antifibrinolytic drug aprotinin, widely used to reduce perioperative bleeding in patients undergoing cardiac surgery, could cause renal failure, congestive heart failure, stroke, and death.

Some experts had been concerned about aprotinin (Trasylol) ever since its approval in 1993.1 As Hiatt explains in his Perspective article in this issue of the Journal (pages 2171–2173), one of two epidemiologic studies reported early this year provided support for this concern. In an observational study involving 4374 patients who underwent coronary revascularization,2 Mangano et al. found that patients who were given aprotinin had an incidence of postoperative renal failure requiring dialysis that was more than twice that among patients who received different agents. Among patients undergoing uncomplicated coronary-artery surgery, those given aprotinin had a 55% increase in the incidence of myocardial infarction or heart failure and a 181% increase in the incidence of stroke or encephalopathy. The authors advised against further use of the drug, since safer, cheaper alternatives are available.

After the study was published, the FDA moved to convene an advisory committee to reassess the drug's safety and assembled the relevant data. The committee met on September 21, reviewed the available evidence, and concluded that there was no need for additional warnings on the drug's official labeling.

What put aprotinin on the front page on September 30, however, was the revelation that its manufacturer, Bayer, had hired a private contract research organization to perform its own large observational study of postoperative complications in patients given the drug. The analysis, completed in time for the FDA meeting, reached conclusions similar to those of Mangano et al. It, too, adjusted for a wide variety of clinical characteristics and showed that patients who received aprotinin had higher mortality rates and substantially more renal damage than those given other treatments. But neither Bayer nor its contractor had provided the report to the FDA or even acknowledged its existence before the meeting.

FDA Revises Labeling on Trasylol

The U.S. Food and Drug Administration (FDA) today approved revised labeling for Trasylol (aprotinin injection) to strengthen its safety warnings and to limit its approved usage to specific situations. Trasylol is given to patients before heart surgery to reduce bleeding and the need for blood transfusions. Trasylol is marketed by Bayer Pharmaceuticals Corporation, Leverkusen, Germany.

"The purpose of the label change is to inform physicians and patients about the risks associated with Trasylol and to ensure they understand the new warnings and use the product as directed by the label," said Steven Galson, M.D., MPH, Director of FDA's Center for Drug Evaluation and Research.

The new labeling specifies that Trasylol should only be given to patients who are at an increased risk for blood loss and blood transfusion in the setting of coronary bypass graft surgery (a procedure used to improve blood flow to the heart) when patients undergo cardiopulmonary bypass (a procedure that allows a machine to take over the heart's functions when it is stopped during surgery). The changes also include a warning that Trasylol increases the possible risk for kidney damage, and suggest ways to manage and reduce the patient's risk for hypersensitivity (exaggerated immune) reactions.

The labeling changes follow an FDA-conducted review of safety information that FDA became aware of after the product was introduced to the market. FDA began this safety review of Trasylol in January 2006. The review was triggered by the results of two published research studies. One study reported an increase in the possibility of kidney failure, heart attack and stroke in patients treated with Trasylol compared to those treated with other drugs. The other study reported an increase in the possibility of kidney damage compared to other drugs, but did not show an increased risk of heart attack or stroke. On February 8, 2006, FDA issued a Public Health Advisory regarding these new findings with Trasylol. On September 21, 2006, FDA held a public meeting of the Cardiovascular and Renal Drugs Advisory Committee to discuss the safety and overall risk-benefit profile for Trasylol. At that meeting, the committee discussed the findings from the two published observational studies, a Bayer worldwide safety review, and the FDA review of its own post-marketing database, and made recommendations for labeling changes. The labeling changes for Trasylol are based upon the recommendations of that advisory committee.

FDA announced on September 29, 2006, that Bayer informed the agency of an additional safety study on September 27, 2006. The preliminary results from that study suggest that in addition to serous kidney damage, Trasylol may increase the chance for death, congestive heart failure (a weakening of the heart), and strokes. The FDA review of this additional Trasylol safety information is continuing and it may result in other actions, including additional changes to the labeling. For additional information about Trasylol, see www.fda.gov/cder/drug/infopage/aprotinin/default.htm.

FDA Issues A Safety Alert on Avandia

The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. However, other published and unpublished data from long-term clinical trials of Avandia, including an interim analysis of data from the RECORD trial (a large, ongoing, randomized open label trial) and unpublished reanalyses of data from DREAM (a previously conducted placebo-controlled, randomized trial) provide contradictory evidence about the risks in patients treated with Avandia.

Patients who are taking Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack should talk to their doctor about this new information as they evaluate the available treatment options for their type 2 diabetes.

FDA's analyses of all available data are ongoing. FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies. Pending questions include whether the other approved treatment from the same class of drugs, pioglitazone, has less, the same or greater risks. Furthermore, there is inherent risk associated with switching patients with diabetes from one treatment to another even in the absence of specific risks associated with particular treatments. For these reasons, FDA is not asking GlaxoSmithKline, the drug's sponsor, to take any specific action at this time. FDA is providing this emerging information to prescribers so that they, and their patients, can make individualized treatment decisions.

"FDA remains committed to assuring that doctors and patients have the latest information available to make treatment and medication use decisions. In this case, FDA is carefully weighing several complex sources of data, some of which show conflicting results, related to the risk of heart attack and heart-related deaths in patients treated with Avandia," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "We will complete our analyses and make the results available as soon as possible. FDA will take the issue of cardiovascular risk associated with Avandia and other drugs in this class to an Advisory Committee as soon as one can be convened."

Avandia was approved in 1999 for treatment of type 2 diabetes, a serious and life threatening disease that affects about 18 to 20 million Americans. Diabetes is a leading cause of coronary heart disease, blindness, kidney failure and limb amputation. Since the drug was approved, FDA has been monitoring several heart-related adverse events (e.g., fluid retention, edema and congestive heart failure) based on signals seen in previous controlled clinical trials of Avandia alone and in combination with other drugs, and from postmarketing reports. FDA has updated the product's labeling on several occasions to reflect these new data, most recently in 2006. The most recent labeling change for Avandia also included a new warning about a potential increase in heart attacks and heart-related chest pain in some individuals using Avandia. This new warning was based on the result of a controlled clinical trial in patients with existing congestive heart failure.

Recently, the manufacturer of Avandia provided FDA with a pooled analysis (meta analysis) of 42 randomized, controlled clinical trials in which Avandia was compared to either placebo or other anti-diabetic therapies in patients with type 2 diabetes. The pooled analysis suggested that patients receiving short-term (most studies were 6-months duration) treatment with Avandia may have a 30-40 percent greater risk of heart attack and other heart-related adverse events than patients treated with placebo or other anti-diabetic therapy. These data, if confirmed, would be of significant concern since patients with diabetes are already at an increased risk of heart disease.